盐酸艾司洛尔(Esmolol Hydrochloride) - 药物靶点：β1-adrenergic receptor_在研适应症：糖尿病足溃疡，室性心律失常，高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(±)-esmolol、(±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate、3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester

+ [16]

靶点

β1-adrenergic receptor

作用方式

拮抗剂

作用机制

β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [1]

在研适应症

糖尿病足溃疡室性心律失常高血压+ [2]

非在研适应症-

原研机构

Baxter International, Inc.

在研机构

HQ Specialty Pharma Corp.Baxter Healthcare Corp.

NovaLead Pharma Pvt Ltd.

+ [1]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1986-12-31),

高血压室上性心动过速心动过速

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H26ClNO4

InChIKeyGEKNCWBANDDJJL-UHFFFAOYSA-N

CAS号81161-17-3

关联

190

项与盐酸艾司洛尔相关的临床试验

NCT06958393

/ Not yet recruiting临床4期IIT

Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery: a Single-centre, Prospective, Randomized Controlled Trial

Background Postoperative delirium (POD) is a common acute and transient form of brain dysfunction in elderly patients following surgery that can lead to serious adverse clinical outcomes and even death. Although existing studies have preliminarily investigated the effects of opioid-free anaesthesia (OFA) on POD, high-quality evidence on these effects for elderly patients undergoing gastrointestinal surgery remains limited. This study aims to investigate the effects of OFA on the development of POD in elderly patients following gastrointestinal surgery.
Methods and analysis:
This single-centre, prospective, randomized controlled trial will be conducted at the First Affiliated Hospital of Shandong First Medical University, China. A total of 406 patients aged 65 years or older who are scheduled for elective gastrointestinal surgery will be randomly allocated to receive either opioid-free anaesthesia (OFA; dexmedetomidine, esmolol, and esketamine) or conventional opioid-based anaesthesia (OBA). The primary outcome is the incidence of POD 7 days after surgery. The secondary outcomes are all-cause mortality within 30 days after surgery, intraoperative haemodynamic changes, the 15-item quality of recovery (QoR-15) scores at 24 h, 48 h, and 72 h after surgery, complications during postoperative hospitalization, pain numerical rating scale (NRS) score at 72 h after surgery, incidence of nausea and vomiting at 72 h after surgery, morphine milligram equivalent for analgesics at 72 h after surgery, duration of anaesthesia (from induction to discontinuation), duration of surgery (from skin incision to the last suture), duration of post-anaesthesia care unit (PACU) stay, and length of hospital stay.
Discussion:
The results of this study may shed light on the effects of OFA on POD in elderly patients undergoing gastrointestinal surgery. The study is designed on the basis of the following key hypothesis: the use of opioid drugs for anaesthesia may increase the risk of POD through mechanisms such as blood-brain barrier destruction, neuroinflammatory responses, and central nervous system depression. Through the single-centre and prospective design of this randomized controlled trial, this study will directly analyse differences in the effects of OFA and conventional OBA on the incidence of POD, haemodynamic stability and long-term cognitive function in elderly patients.
gastrointestinal surgery.

开始日期2025-05-20

申办/合作机构

山东第一医科大学第一附属医院（山东省千佛山医院、山东省牙病防治指导中心）

CTRI/2025/03/082812

/ Not yet recruiting临床3期IIT

A randomised study to compare the effects of i.v Esmolol vs i.v Labetalol in attenuating hemodynamic response during extubation in Department of Anesthesia, S.M.S Medical College Jaipur - nil

开始日期2025-03-22

申办/合作机构-

ChiCTR2500096874

/ SuspendedN/AIIT

The effects of esmolol on intraoperative stress response and inflammatory response in orthopedic surgery patients

开始日期2025-02-13

申办/合作机构-

100 项与盐酸艾司洛尔相关的临床结果

登录后查看更多信息

100 项与盐酸艾司洛尔相关的转化医学

登录后查看更多信息

100 项与盐酸艾司洛尔相关的专利（医药）

登录后查看更多信息

2,348

项与盐酸艾司洛尔相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Effects of esketamine infusion on tourniquet-induced hypertension in patients undergoing below-knee orthopedic surgery: protocol for a randomized controlled trial

Article

作者: Ying, Yao-yu ; Shi, Hai-jing ; Ji, Fu-hai ; Jiang, Kai ; Peng, Ke ; Zhuang, Min-yuan ; Zhao, Wen-qian

INTRODUCTION:

Application of a tourniquet reduces surgical bleeding while causing pain and tourniquet-induced hypertension (TIH). Deeper anesthesia and additional opioids are often insufficient to mitigate TIH but are associated with prolonged recovery and complications. Herein, we describe the protocol for a clinical trial investigating whether intraoperative esketamine infusion would reduce the rate of TIH during below-knee orthopedic surgery.

PATIENTS AND METHODS:

This prospective, randomized, double-blind, controlled trial will include a total of 80 adults scheduled for below-knee orthopedic surgery under general anesthesia. Patients will be randomly assigned in a 1:1 ratio to receive either esketamine infusion at 0.25 mg/kg/h or normal saline infusion after anesthesia induction and during tourniquet inflation. Both groups will receive ultrasound-guided unilateral popliteal sciatic nerve block and adductor canal block with 0.25% ropivacaine. The primary outcome is the occurrence of TIH, defined as an increase in systolic blood pressure >30% of baseline during tourniquet inflation. Secondary outcomes include the incidence of hypotension during surgery; intraoperative hemodynamic changes; intraoperative opioid dose and total amount of esmolol; postoperative nausea and vomiting, dizziness, and mental side effects; postoperative pain at 1, 6, 12, and 48 h after surgery; postoperative analgesic consumption within 48 h after surgery; and length of postoperative hospital stay. Additionally, we will assess patients' quality of recovery at 24 h after surgery.

DISCUSSION:

This trial will determine the effects of esketamine infusion on TIH in patients who undergo below-knee orthopedic surgery under general anesthesia. Our results will offer a new insight into optimizing anesthetic care for surgical patients receiving tourniquet.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR2400081237).

2025-08-01·TALANTA

Fabrication and evaluation of stationary phases with different morphology from two imidazole-based ligands for nonchiral and chiral electrochromatographic separation

Article

作者: Bai, Liming ; Gao, Lidi ; Chen, Mo ; Liang, Xinyu ; Liu, Shuren ; Zhao, Ming ; Zhao, Fuquan ; Qin, Shili ; Hou, Yuanyuan ; Chu, Hongtao

In this work, two metal-organic porous materials from the two imidazole-based ligands (4-methylimidazole-5-carbaldehyde (aImeIm) and histidine (His)) and the same metal source (Zn(CH₃COO)₂·2H₂O), namely His-ZIF-93 with a crystal zeolite imidazolate framework and His/aImeIm@Zn with an amorphous networks, were first designed and synthesized by the one-pot method. They were used as the stationary phases (SPs) of open-tubular capillary electrochromatography (OT-CEC) to evaluate and compare their separation performance for the nonchiral and chiral compounds. His-ZIF-93-bonded OT-CEC column successfully separated five families of nonchiral analytes due to the synergistic effect of His and the crystal framework. The separation mechanism included electrostatic interaction, molecular sieve effect, π-π interaction, electrophoretic mobility, hydrogen bonding interaction, and so on. His/aImeIm@Zn-bonded OT-CEC column exhibited a more superior enantioseparation capability for seven chiral compounds with an ultrahigh column efficiency of 7.6 × 10⁵ plates/m due to a large number of chiral sites and the porous networks. Enantioseparation were attributed to the difference of adsorption and selectivity between the SPs and the two enantiomers through the adsorption experiments and the binding constants tests. Thus, both His-ZIF-93-bonded OT-CEC column and His/aImeIm@Zn-bonded OT-CEC column demonstrated the universality for the analytes, as well as excellent reproducibility, satisfactory stability and long lifetime.

2025-06-01·SHOCK

VERY EARLY USE OF ESMOLOL IN HYPERKINETIC SEPTIC SHOCK PATIENTS WITH PERSISTENT TACHYCARDIA: A RANDOMIZED CONTROLLED PILOT STUDY

Article

作者: He, Hong-li ; Huang, Xiao-bo ; Hernández, Glenn ; Lu, Sen ; Pan, Chun ; Kattan, Eduardo ; Luo, Jing-chao ; Chen, Yue ; Zhang, Tao ; Wang, Ping ; Shen, Jun

ABSTRACT:

Background: Although β-blockade for heart rate (HR) control in septic shock is conventionally initiated after 24 h of stabilization in most studies, we investigated whether esmolol could be safely and effectively administered immediately postinitial resuscitation in hyperkinetic septic shock patients with persistent tachycardia. Methods: In this randomized controlled pilot study, 24 hyperkinetic septic shock patients with sinus tachycardia (>95 bpm) after initial resuscitation were randomized to receive either esmolol (titrated for 10% HR reduction) as the treatment group or equal volume of normal saline as the control group. The primary endpoint was achievement of target HR reduction, with safety assessed through monitoring of tissue perfusion parameters and hemodynamic stability over 72 h. Results: Demographic and baseline characteristics were comparable between groups. The esmolol group achieved faster HR reduction (12/12 vs. 7/12 patients at 24 h, P = 0.037) with comparable hemodynamic stability. Despite initial decreases in cardiac index (4.5 ± 0.9 to 3.9 ± 0.6 L/min/m2, P = 0.009) and oxygen delivery index (585 ± 145 to 504 ± 132 mL, P = 0.040) at 1 h, tissue perfusion parameters remained stable. No significant between-group differences were observed in central venous oxygen saturation, CO2 gap, microcirculation parameters, inflammatory markers, organ functions, or hospital mortality (42% vs. 42%, P = 1.000). Conclusion: This pilot study suggested that post-initial resuscitation early esmolol administration targeting modest HR reduction appears feasible and safe in hyperkinetic septic shock patients with persistent tachycardia, providing foundation for future large-scale investigations.

168

项与盐酸艾司洛尔相关的新闻（医药）

2025-05-28

·鲁抗医药

鲁抗医药携新产品参加第90届全国药交会

5月21-23日，备受瞩目的第90届全国药品交易会在广州国际会展中心完美落幕。股份公司、赛特公司、青海大地公司、国贸公司、鲁抗好丽友营销团队携旗下重磅产品及创新成果亮相展会。本次展台展现了公司持续的创新成果，分区展示了公司新上市产品和即将上市产品，全方位呈现了公司的研发实力和产品布局。股份公司重点展示了降糖类和心脑血管类产品，如阿卡波糖片、瑞舒伐他汀钙片、依折麦布片、阿哌沙班片、苯磺酸左氨氯地平片；赛特公司重点展示了降糖类药品利格列汀片和控制心律失常和围手术期高血压的急抢救药盐酸艾司洛尔注射液；青海大地公司展示了7大独家产品，如参鹿扶正胶囊、润肺止咳胶囊等；鲁抗好丽友展示了即将上市的肠癌诊断试剂。本次鲁抗医药的惊艳亮相，不仅和老朋友拓展了业务合作领域，还结识了许多潜在客户和合作伙伴，同时深入了解了当前医药市场的最新趋势和未来创新发展方向。鲁抗医药将持续致力于新旧动能转换，加快在创新药、高端制剂、生物制造等方面实现突破，持续提升产品链综合竞争力，不断塑造高质量发展新优势，创新突破，引领未来。为期三天的展位前人头攒动，热度非凡，气氛异常热烈。

诊断试剂

2025-05-19

·药筛

药交会前瞻：最卷的100个药品

参加广州药交会，提前做好产品攻略！纯干货，无废话。这是系列四：2024年1月1日-2025年4月30日获批企业数量排名前100药品。排名药品名称持有人数量1地夸磷索钠滴眼液362间苯三酚注射液343乳果糖口服溶液304米诺地尔搽剂295二羟丙茶碱注射液276玻璃酸钠滴眼液267法莫替丁注射液268他达拉非片269硫酸氨基葡萄糖胶囊2510帕拉米韦注射液2311磷酸奥司他韦干混悬剂2212磷酸奥司他韦胶囊2213己酮可可碱注射液2114氨溴特罗口服溶液2015复方聚乙二醇电解质散(III)1916注射用尼可地尔1917达格列净片1718利丙双卡因乳膏1719罗沙司他胶囊1720吸入用乙酰半胱氨酸溶液1721恩格列净片1622盐酸乌拉地尔注射液1623阿戈美拉汀片1524富马酸福莫特罗吸入溶液1525硫酸镁钠钾口服用浓溶液1526注射用盐酸罗沙替丁醋酸酯1527磷酸西格列汀片1428马来酸阿伐曲泊帕片1429美索巴莫注射液1430盐酸多巴酚丁胺注射液1431吲哚布芬片1432注射用氯诺昔康1433甲钴胺片1334氯化钾颗粒1335氯化钾注射液1336马来酸氟伏沙明片1337普拉洛芬滴眼液1338沙库巴曲缬沙坦钠片1339腺苷钴胺胶囊1340盐酸奥洛他定滴眼液1341盐酸达泊西汀片1342注射用头孢唑肟钠1343二甲双胍恩格列净片(Ⅰ)1244富马酸伏诺拉生片1245盐酸艾司洛尔注射液1246盐酸多巴胺注射液1247盐酸莫西沙星滴眼液1248盐酸莫西沙星氯化钠注射液1249艾曲泊帕乙醇胺片1150普瑞巴林胶囊1151瑞巴派特片1152西格列汀二甲双胍片(Ⅱ)1153盐酸氨溴索口服溶液1154盐酸丙卡特罗口服溶液1155地氯雷他定口服溶液1056非布司他片1057硫酸镁注射液1058麦考酚钠肠溶片1059盐酸去氧肾上腺素注射液1060盐酸左沙丁胺醇雾化吸入溶液1061左氧氟沙星滴眼液1062阿加曲班注射液963枸橼酸西地那非口崩片964拉考沙胺注射液965莫匹罗星软膏966普瑞巴林口服溶液967氢溴酸伏硫西汀片968瑞戈非尼片969重酒石酸间羟胺注射液970重酒石酸去甲肾上腺素注射液971注射用头孢他啶阿维巴坦钠972左乙拉西坦口服溶液973阿司匹林肠溶片874布洛芬混悬液875地诺孕素片876多巴丝肼片877多索茶碱注射液878二甲双胍恩格列净片(Ⅵ)879甲硫酸新斯的明注射液880聚乙烯醇滴眼液881硫酸羟氯喹片882铝碳酸镁咀嚼片883米拉贝隆缓释片884舒更葡糖钠注射液885碳酸氢钠林格注射液886头孢地尼颗粒887吸入用硫酸沙丁胺醇溶液888硝酸异山梨酯注射液889熊去氧胆酸胶囊890溴芬酸钠滴眼液891依折麦布片892左卡尼汀口服溶液893艾司奥美拉唑镁肠溶胶囊794奥拉帕利片795奥美沙坦酯氨氯地平片796奥硝唑注射液797倍他米松磷酸钠注射液798吡拉西坦注射液799富马酸丙酚替诺福韦片7100钆特酸葡胺注射液7101枸橼酸托法替布片7102骨化三醇软胶囊7103甲磺酸雷沙吉兰片7104酒石酸溴莫尼定滴眼液7105聚乙二醇4000散7106利奈唑胺葡萄糖注射液7107硫酸沙丁胺醇注射液7108硫酸特布他林雾化吸入用溶液7109罗库溴铵注射液7110洛索洛芬钠凝胶贴膏7111氯化钾口服溶液7112他氟前列素滴眼液7113碳酸镧咀嚼片7114维格列汀片7115西甲硅油乳剂7116吸入用复方异丙托溴铵溶液7117吸入用盐酸丙卡特罗溶液7118缬沙坦氨氯地平片(Ⅰ)7119盐酸胺碘酮注射液7120盐酸氮卓斯汀滴眼液7121依帕司他片7122注射用厄他培南钠7123左卡尼汀注射液7124左西孟旦注射液7125左氧氟沙星氯化钠注射液7126左氧氟沙星片7（手工整理，如有错误或遗漏，欢迎补充）用摩熵药筛小程序，快速查询产品信息。

申请上市

2025-04-13

·摩熵医药

近80亿β受体阻滞剂市场：阿斯利康、齐鲁、默克三强争霸

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。在心血管疾病治疗领域，β受体阻滞剂占据着举足轻重的地位。从2015年到2022年，我国β受体阻滞剂市场规模一路攀升，年复合增长率达9.87% ，在2022年达到峰值83.26亿元。然而，2023年受集采影响，市场规模下滑至 78.35亿元。这一市场中，109家企业角逐32个品种。阿斯利康凭借琥珀酸美托洛尔缓释片，五年累计销售额超 200 亿元；齐鲁制药、默克等药企也各展身手。不同代际的β受体阻滞剂在临床上的使用情况差异明显，第二代广泛应用，第三代崭露头角。那么，在这风云变幻的市场中，各企业和品种究竟有着怎样的竞争策略与发展态势？本文基于摩熵咨询《β受体阻滞剂市场研究专题报告》，向读者剖析β受体阻滞剂的各类产品布局、市场表现与企业竞争格局，揭示β受体阻滞剂领域的竞争逻辑与未来趋势。01β受体阻滞剂市场概览据统计，2023年β受体阻滞剂市场规模近80亿元，生产企业数量高达109家。根据摩熵医药数据库统计显示，我国β受体阻滞剂市场规模从2015年的43.09亿元上升至2022年的峰值83.26亿元，年复合增长率为9.87%，2023年整体市场规模受集采影响，下滑至78.35亿元，同比下降5.9%。品种/企业数量方面，2023年β受体阻滞剂合计品种数量达32个，生产企业数量高达109家。图片来源：摩熵医药《β受体阻滞剂市场研究专题报告》02β受体阻滞剂企业竞争格局 01阿斯利康位列企业销售排行榜首，五年累计销售额超200亿元我国β受体阻滞剂市场的领先企业为阿斯利康。根据摩熵医药数据库统计显示，2019-2023年合计销售额约201.58亿元，包括医院端销售额151.97亿元，药店端销售额49.61亿元，阿斯利康为唯一一家近五年累计销售额突破200亿元的企业。外资药企中，默克在我国β受体阻滞剂市场也占据重要市场份额，2019-2023年合计销售额约42.94亿元，展现出较强的市场竞争力。国内药企中，齐鲁制药取得不俗的销售表现，其2019-2023年合计销售额约48.50亿元，位列企业排行榜第二位。阿斯利康、齐鲁制药及默克三家企业为第一梯队，其余企业销售额较小，总体竞争格局较分散。2019-2023年β受体阻滞剂累计销售额企业排行榜02凭借核心重磅产品，第一梯队企业已建立起稳固的竞争优势阿斯利康旗下主要产品为琥珀酸美托洛尔缓释片，商品名为倍他乐克，这款产品是β受体阻滞剂第一大品种，除治疗高血压外，在心率失常、心力衰竭、心绞痛等领域也应用广泛，被誉为心脑内科用药“万金油”。默克旗下主打产品为富马酸比索洛尔片，为β受体阻滞剂类药物第二大品种，也是心血管疾病的首选药物之一。齐鲁制药旗下主要品种为盐酸艾司洛尔注射液，这款产品为β受体阻滞剂类药物第三大品种，也是治疗心动过速、主动脉夹层、围手术期高血压等的一线药物。图片来源：摩熵医药销售数据库、摩熵医药全球药物研发数据库03β受体阻滞剂品种竞争格局 01前十大品种占据76%的市场，第二代药物目前在临床上使用最广泛据摩熵医药销售数据库显示，在2023年全国医院销售额TOP10中，销售额最大的品种为琥珀酸美托洛尔缓释片，年销售额约24.98亿元，其次为盐酸艾司洛尔注射液（11.42亿元）和富马酸比索洛尔片（8.63亿元）。排名前十的品种合计销售额约59.23亿元，占2023年总销售额的75.60%。目前我国临床使用最广泛的β受体阻滞剂为第二代药物，2023年第二代β受体阻滞剂市场份额约85.13%，占据绝对主导地位。第一代已逐渐被市场淘汰，市场份额小于5%，第三代药物由于疗效更显著、安全性更佳逐渐受到市场关注，2023年其市场份额已超过10%。图片来源：摩熵医药《β受体阻滞剂市场研究专题报告》02美托/比索洛尔集采后份额下降，艾司/阿罗洛尔市场份额快速提升品种竞争格局方面，2023年市场份额排名前四的品种依次为美托洛尔（52.26%）、比索洛尔（16.18%）、艾司洛尔（16.02%）、阿罗洛尔（5.78%），历年各品种份额虽稍有波动，但整体来看，前四大品种份额次序相对稳定。β受体阻滞剂类药物中，比索洛尔首个进入第二批国采，美托洛尔口服常释剂型纳入第五批国采，缓控释剂型纳入第七批国采。集采后，美托/比索洛尔合计市场份额从2019年的81.93%降至2023年的68.44%。艾司洛尔、第三代品种阿罗洛尔市场份额则快速提升，根据摩熵医药数据库统计显示，艾司洛尔市场份额从2019年的8.09%上升至2023年的16.02%。截止2024年10月，有20家仿制药企的艾司洛尔通过/视同通过一致性评价。目前其已中选第十批国采，现有竞争格局将重塑。图片来源：摩熵医药销售数据库结语综上所述，我国β受体阻滞剂市场在过往数年经历了增长与调整。集采政策深刻影响了市场格局，美托洛尔、比索洛尔等品种市场份额下降，而艾司洛尔、阿罗洛尔等则迎来发展机遇。阿斯利康、齐鲁制药、默克等药企凭借核心产品在竞争中脱颖而出。随着医药技术的持续进步和市场环境的不断变化，未来β受体阻滞剂市场必将更加精彩。第三代药物有望凭借其优势进一步拓展市场，更多药企也可能凭借创新产品或优化策略实现突破。让我们拭目以待，共同见证这一市场的下一段发展历程。END本文为原创文章，转载请留言获取授权β受体阻滞剂市场研究专题报告下期内容预告目录一、50亿「洛尔一哥」跌落！AZ失守70%市场，齐鲁、苑东生物靠集采狂抢份额近期将持续更新，敬请期待近期热门资源获取CGT产业现状与未来趋势蓝皮书-202406中药行业现状与未来趋势白皮书-2024072023年医药企业综合实力排行榜-202408跨越国界，引领创新：中国药企出海的布局实践-202408专利即将到期五大重磅小分子药品，国内仿制药“战况”几何?-202409中国放射性药物市场现状分析报告-202410合成生物产业发展前景及中国合成生物产业链上中下游企业分析-202410中国合成生物学创投市场分析报告-202410中国糖尿病临床诊疗与药物多渠道市场数据分析-202411基于剂型改良的复杂注射剂分析--微球篇-2024112024医美注射材料市场发展分析报告-20241213国家药品集采跟踪报告-前9批次集采回顾与展望-202411近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

带量采购医药出海核酸药物

100 项与盐酸艾司洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00644	盐酸艾司洛尔	C07AB09	DB00187

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病足溃疡	印度	NovaLead Pharma Pvt Ltd.	2024-04-24
室性心律失常	日本	Maruishi Pharmaceutical Co., Ltd.	2002-10-08
高血压	美国	Baxter Healthcare Corp.	1986-12-31
心动过速	美国	Baxter Healthcare Corp.	1986-12-31
室上性心动过速	美国	Baxter Healthcare Corp.	1986-12-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04181606 (CTgov)	早期临床1期	-	30	Isometric handgrip exercise+Esmolol infusion (Esmolol Infusion)	積獵範壓積鬱醖糧醖簾(餘顧網糧淵範艱鹽遞衊) = 觸衊簾鏇鑰糧齋膚範積範觸窪鹽願壓鑰選願簾 (窪糧網窪鹽餘襯獵鏇簾, 3.2) 更多	-	2025-05-13
				Saline infusion (Saline Infusion)	積獵範壓積鬱醖糧醖簾(餘顧網糧淵範艱鹽遞衊) = 壓觸衊遞餘廠範憲餘廠範觸窪鹽願壓鑰選願簾 (窪糧網窪鹽餘襯獵鏇簾, 2.4) 更多
NCT04356352 (CTgov)	临床2/3期	疼痛 \| 注射部位反应	33	Lidocaine (Lidocaine)	築襯壓衊選構鏇繭獵襯(夢糧選鏇醖糧廠繭蓋壓) = 繭鹹遞艱憲艱醖壓鑰鹹壓製醖窪觸衊齋繭鹹蓋 (簾顧構鏇鹽構獵網範顧, 0.66) 更多	-	2024-09-19
				Esmolol (Esmolol)	築襯壓衊選構鏇繭獵襯(夢糧選鏇醖糧廠繭蓋壓) = 醖範觸構遞網衊醖鬱範壓製醖窪觸衊齋繭鹹蓋 (簾顧構鏇鹽構獵網範顧, 1.02) 更多
NCT01113515 (CTgov)	临床1/2期	糖尿病足溃疡	44	Placebo gel (Placebo)	壓糧範鹽襯製繭製窪齋 = 選餘顧築簾廠衊繭選網觸構齋襯範艱壓構窪夢 (願鏇廠願夢齋淵鑰齋餘, 夢網鑰壓廠廠願鹽觸築 ~ 夢膚蓋構襯窪淵膚鏇簾) 更多	-	2024-05-20
				Esmolol hydrochloride (Galnobax 20% QD)	壓糧範鹽襯製繭製窪齋 = 廠繭糧鹽艱範糧觸淵淵觸構齋襯範艱壓構窪夢 (願鏇廠願夢齋淵鑰齋餘, 齋餘襯積鑰憲窪壓廠鑰 ~ 繭積選夢網膚餘積膚衊) 更多
NCT03998436 (CTR/2018/11/016295 \| ###DELETE, CTgov)	临床3期	糖尿病足溃疡	176	Esmolol Hydrochloride (Galnobax® 14% Gel Plus SoC)	齋鑰網築積積觸獵選廠 = 鏇範淵壓築觸網鹹鏇淵繭鬱獵襯願憲窪鑰觸積 (願餘觸夢獵遞廠鑰壓鬱, 鏇艱選願築觸蓋淵鬱鹹 ~ 醖餘獵鹽襯餘鑰醖鑰簾) 更多	-	2023-09-22
				Only Standard of Care (SoC Only)	齋鑰網築積積觸獵選廠 = 淵蓋製艱淵範夢鬱糧壓繭鬱獵襯願憲窪鑰觸積 (願餘觸夢獵遞廠鑰壓鬱, 鏇鏇蓋糧遞廠觸選製蓋 ~ 窪網獵積艱顧憲餘壓遞) 更多
NCT03998436 \| CTRI/2018/11/016295 (Pubmed)	临床3期	糖尿病足溃疡	176	Esmolol with SoC	齋夢醖網餘壓遞網鏇蓋(淵鑰艱鏇願網鹽襯遞範) = 衊膚築襯鹹壓憲鏇鹹壓衊鏇積夢積鏇願鑰顧夢 (製觸觸繭鹽簾糧願蓋遞 ) 更多	-	2023-05-01
				Topical Esmolol Hydrochloride (SoC only)	齋夢醖網餘壓遞網鏇蓋(淵鑰艱鏇願網鹽襯遞範) = 醖願襯構顧製淵廠鏇積衊鏇積夢積鏇願鑰顧夢 (製觸觸繭鹽簾糧願蓋遞 ) 更多
CTRI/2013/07/003838 \| NCT01113515 (Pubmed)	临床1/2期	糖尿病足溃疡	-	Galnobax 14%	積網鑰鏇製願壓壓鹽糧(廠夢鏇餘膚獵艱蓋衊觸) = 鬱積淵廠餘糧淵艱簾製製膚鏇遞築簾餘衊鬱獵 (範鑰構夢顧窪構鬱製艱 ) 更多	-	2022-10-16
				Galnobax 20%	積網鑰鏇製願壓壓鹽糧(廠夢鏇餘膚獵艱蓋衊觸) = 繭範窪鬱淵願選窪廠觸製膚鏇遞築簾餘衊鬱獵 (範鑰構夢顧窪構鬱製艱 ) 更多
NCT02369900 (Pubmed)	临床2期	脓毒性休克	40	Esmolol	鬱膚醖艱膚觸憲糧觸鑰(鏇艱醖積顧觸製膚鹹壓) = 網窪衊襯壓衊遞蓋艱鹹鏇衊衊鏇範鬱遞遞糧憲 (窪鏇淵顧壓構鹽廠願網 )	-	2021-12-27
				Placebo	鬱膚醖艱膚觸憲糧觸鑰(鏇艱醖積顧觸製膚鹹壓) = 製顧衊夢鑰廠膚襯積繭鏇衊衊鏇範鬱遞遞糧憲 (窪鏇淵顧壓構鹽廠願網 )
NCT02369900 (CTgov)	临床2期	脓毒性休克 \| 低血压 \| 心动过速	40	Esmolol (Esmolol Infusion)	積築艱夢簾顧遞窪遞選(夢願壓糧餘鑰鑰艱網觸) = 鏇願壓憲製醖醖範鹽顧糧憲鏇鏇襯襯膚製憲艱 (觸簾製夢艱淵選膚淵範, 0.17) 更多	-	2021-06-28
				saline (Standard Care, Saline)	積築艱夢簾顧遞窪遞選(夢願壓糧餘鑰鑰艱網觸) = 簾醖範鑰築鹹醖餘齋範糧憲鏇鏇襯襯膚製憲艱 (觸簾製夢艱淵選膚淵範, 0.19) 更多
NCT02466542 (Pubmed \| Eur J Anaesthesiol)	临床4期	疼痛	-	Esmolol infusion	艱襯壓蓋艱鹽鬱襯願蓋(網網積窪觸艱鏇簾憲艱) = 選鹹鏇積鏇齋簾繭築糧範蓋鹽膚鬱鹽鬱衊積憲 (艱糧鹹範顧窪製醖築鹽, -13.4 ~ -0.31)	积极	2021-04-08
NCT03661346 (CTgov)	临床2期	出血 \| 慢性鼻窦炎	28	Esmolol (Esmolol)	蓋範窪網繭繭遞獵廠餘(鏇顧蓋構糧襯淵鬱構鑰) = 糧簾淵夢構鹽繭齋衊遞蓋顧選淵繭鑰廠夢鏇膚 (構壓憲鬱襯夢齋餘夢構, .69) 更多	-	2021-02-08
				Labetalol (Labetalol)	蓋範窪網繭繭遞獵廠餘(鏇顧蓋構糧襯淵鬱構鑰) = 蓋選齋願糧艱蓋廠積選蓋顧選淵繭鑰廠夢鏇膚 (構壓憲鬱襯夢齋餘夢構, .89) 更多